Ipsen Acquires Memo Therapeutics in Strategic $800 Million Biotech Deal

Ipsen’s €700M+ acquisition of Memo Therapeutics strengthens its pipeline with potravitug, a promising targeted therapy aiming to address a major unmet need in kidney transplant care.

Ipsen acquires Memo therapeutics after reaching an agreement to buy Swiss Biotech Memo Therapeutics AG for 200 million euros up front, with further milestone-based payments that could raise the amount to above 700 million euros, or about $800 million.

According to the company, the arrangement focuses on potravitug, a Phase II monoclonal antibody that targets BK polyomavirus-associated nephropathy, a condition in kidney transplant recipients that can result in graft loss and transplant failure. As of right now, there are no approved targeted treatments for the illness, and clinical management entails cutting back on immunosuppressive medication, which increases the chance of graft rejection.

The acquisition of Memo Therapeutics marks a strategic step for Ipsen into addressing critical unmet needs in transplant medicine, with potravitug offering a potential breakthrough approach for patients facing BK polyomavirus-associated complications.

According to the recent analytical review by CIO Bulletin, Ipsen would transfer 200 million euros upon closing on a cash-and-debt-free basis, with the remaining amount being structured as deferred payments subject to meeting development, regulatory, and commercial milestones. Ipsen has already included the financial impact in its guidance for the entire year, and closing is expected by the end of the third quarter, subject to regular regulatory and contractual sign-offs.

All of Memo Therapeutics' non-potravitug assets, including its employees, the DROPZYLLA antibody discovery platform, and a partnership with CSL, will be spun into a new company named Memorises Bio, which will be owned by Memo's current shareholders.

Potravitug prevents viral replication by inhibiting the BK virus from adhering to and penetrating host cells. The medication was designated as an orphan medicine by the European Union in December 2025 and as a fast-track drug by the FDA in May 2023.

Ipsen's purchase of Memo Therapeutics represents a more general trend in the biotechnology industry toward funding highly tailored treatments intended to address intricate medical problems.